Key result
This article reviews the role of platelets, mechanisms of platelet activation, and results of platelet-inhibitory drug trials in patients with coronary artery disease.
This review summarizes the mechanisms of platelet activation and the role of platelet-inhibitory drugs in coronary artery disease.
Answers are grounded in this paper and cite their sources.
Offers synthesis of platelet inhibition evidence in CAD; leaves open questions on personalized approaches.
THE ROLE of platelets in the genesis of atherosclerosis and its manifestations has received considerable attention. Based on the recognition of platelet "hyperactivity" in patients with coronary artery disease, several platelet-suppressive drugs have been used in a large number of patients. The purpose of this article is to review the role of platelets, the mechanisms of platelet activation, and the results of platelet-inhibitory drug trials in patients with coronary artery disease. PLATELETS AND HEMOSTASIS Platelets, small disklike cells circulating in the blood, have a primary role in hemostasis. With stress to the endothelium and its subsequent disruption, platelets adhere to the subendothelial collagen. Circulating platelets are attracted to the adhering platelets, resulting in platelet aggregation and formation of a platelet thrombus. In this thrombus, RBCs, WBCs, and other components of blood are incorporated, resulting in an occlusive clot. On activation, platelets also release potent hormones, prostaglandins, polypeptides, and other vasoactive
No takes yet. Share an insight, caveat, or question.
Jawahar L. Mehta (1983) conducted a review in Coronary artery disease. Platelet-inhibitory drugs was evaluated. This article reviews the role of platelets, mechanisms of platelet activation, and results of platelet-inhibitory drug trials in patients with coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: